Asthma, Aspirin-Induced
9
0
1
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
11.1%
1 terminated out of 9 trials
85.7%
-0.8% vs benchmark
22%
2 trials in Phase 3/4
83%
5 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab)
Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease
Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)
Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban
Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease
Role of Inflammatory Mediators in AERD
Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)
The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases
Challenge Test for Acetylsalicylic Acid Hypersensitivity